Market Overview

UPDATE: Goldman Sachs Lowers PT to $22 on Impax Laboratories on Competitive Risks

Related IPXL
Barclays: Impax Labs-Amneal Pharma Merger Creates A Generics Leader
Benzinga's Top Upgrades, Downgrades For May 1, 2018

Goldman Sachs reiterated its Sell rating on Impax Laboratories (NASDAQ: IPXL) and reduced its price target from $24 to $22.

Goldman Sachs commented, "Third quarter revenues and disappointing fourth quarter guidance both suggest that competitive pressures in the generics segment are greater than we had anticipated. Weak Adderall XR sales as well as the further declines implied by guidance suggest that Actavis competition has driven greater-than-anticipated pricing pressure. Fourth quarter guidance was further pressured by earlier-than-expected fenofibrate competition."

Impax Laboratories closed at $24.34 on Friday.

Latest Ratings for IPXL

May 2018BarclaysInitiates Coverage OnOverweight
Apr 2018BMO CapitalMaintainsMarket PerformMarket Perform
Mar 2018SunTrust Robinson HumphreyInitiates Coverage OnBuy

View More Analyst Ratings for IPXL
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (IPXL)

View Comments and Join the Discussion!